Details

Autor(en) / Beteiligte

• Koekenbier, Eva L.
• Fohse, Konstantin
• van de Maat, Josephine S.
• Oosterheert, Jan Jelrik
• van Nieuwkoop, Cees
• Hoogerwerf, Jacobien J.
• Grobusch, Martin P.
• van den Bosch, Maurice A.A.J.
• van de Wijgert, Janneke H.H.
• Netea, Mihai G.
• Rosendaal, Frits R.
• Bonten, Marc J.M.
• Werkhoven, C.H. (Henri) van
• Aardenburg-van Huisstede, Astrid
• Ammerlaan, Heidi S.M.
• Boersma, Willem G.
• Brinkman, Kees
• Bruijning-Verhagen, Patricia C.J.
• van Crevel, Reinout
• Delsing, Corine
• ten Doesschaten, Thijs
• Dofferhoff, Anton S.M.
• Duijkers, Ruud
• Groenwold, Rolf H.H.
• de Haas, Corine
• Hassing, Robert-Jan
• de Hoog, Marieke L.A.
• Huijts, Susanne M.
• van Hylckama-Vlieg, Astrid
• Jong, Eefje
• de Jong, Hanna K.
• Knap, Martijn
• Koenders, Michael
• Kouijzer, Ilse J.E.
• Kramer, Henk
• van de Laar, Roel
• Lalmohamed, Arief
• Lensen, Karel-Jan D.F.
• Lijfering, Willem M.
• Magdelijns, Fabienne
• Meek, Bob
• Middelburg, Rutger A.
• Moeniralam, Hazra S.
• Mooijaart, Simon P.
• van Munster, Barbara C.
• ten Oever, Jaap
• Goossens, Marc Padros
• Peters, Vincent
• Postma, Douwe F.
• Pouw, Niels
• Reesink, Herre J.
• de Regt, Marieke J.A.
• van der Reijden, Anneli C.J.
• Schaakxs, R.
• Slieker, Kitty
• Slingerland, Robbert J.
• van Sluis, Nicolette L.J.
• Stehouwer, Coen D.A.
• van de Veerdonk, Frank
• Verbon, Annelies
• van Werkhoven, C.H. (Henri)

Titel

Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial

Ist Teil von

• Clinical microbiology and infection, 2023-06, Vol.29 (6), p.781-788

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• To test whether Bacillus Calmette-Guérin (BCG) vaccination would reduce the incidence of COVID-19 and other respiratory tract infections (RTIs) in older adults with one or more comorbidities. Community-dwelling adults aged 60 years or older with one or more underlying comorbidities and no contraindications to BCG vaccination were randomized 1:1 to BCG or placebo vaccination and followed for 6 months. The primary endpoint was a self-reported, test-confirmed COVID-19 incidence. Secondary endpoints included COVID-19 hospital admissions and clinically relevant RTIs (i.e. RTIs including but not limited to COVID-19 requiring medical intervention). COVID-19 and clinically relevant RTI episodes were adjudicated. Incidences were compared using Fine-Gray regression, accounting for competing events. A total of 6112 participants with a median age of 69 years (interquartile range, 65–74) and median of 2 (interquartile range, 1–3) comorbidities were randomized to BCG (n = 3058) or placebo (n = 3054) vaccination. COVID-19 infections were reported by 129 BCG recipients compared to 115 placebo recipients [hazard ratio (HR), 1.12; 95% CI, 0.87–1.44]. COVID-19-related hospitalization occurred in 18 BCG and 21 placebo recipients (HR, 0.86; 95% CI, 0.46–1.61). During the study period, 13 BCG recipients died compared with 18 placebo recipients (HR, 0.71; 95% CI, 0.35–1.43), of which 11 deaths (35%) were COVID-19-related: six in the placebo group and five in the BCG group. Clinically relevant RTI was reported by 66 BCG and 72 placebo recipients (HR, 0.92; 95% CI, 0.66–1.28). BCG vaccination does not protect older adults with comorbidities against COVID-19, COVID-19 hospitalization, or clinically relevant RTIs.